The initial success of Sildenafil undeniably transformed the pharmaceutical landscape, but betting in companies heavily reliant on off-patent versions presents a uncertain picture. Although early earnings were substantial, the end of patents and the emergence of less expensive alternatives have diminished market share. Thus, a thorough analysis of